为中国初级角关闭患者开发的患者决策辅助的效果:随机对照试验
Yijie Chen1, Shaodan Zhang2, Yiwen Sun1
1School of Ophthalmology and Optometry, Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Patient preference and adherence
|October 14, 2025
概括
患者决策辅助器 (PDA) 显著减少了决策冲突,并改善了考虑激光外周 iridotomy (LPI) 的初级角度关闭 (PAC) 或初级角度关闭可疑 (PACS) 的患者的知识. 该PDA授权对LPI治疗选择进行知情决策.
科学领域:
- 眼科医生 眼科 眼科
- 医疗决策的制定 医疗决策的制定
- 医疗信息学 医疗信息学
背景情况:
- 主角闭合 (PAC) 和主角闭合疑似 (PACS) 是需要治疗决策的条件,通常涉及激光外周 iridotomy (LPI).
- 有效的患者决策辅助工具 (PDA) 对于向患者提供LPI等治疗选择的信息至关重要.
研究的目的:
- 评估PDA对PACS或PAC评估LPI的患者的决策过程的影响.
- 为了确定PDA是否影响与LPI治疗相关的决策冲突,知识,满意度和遗憾.
主要方法:
- 一项随机对照试验涉及107名参与者,他们接受了PACS或PAC.
- 参与者被分配到对照组 (知情同意表) 或干预组 (PDA).
- 干预后测量了决策冲突,知识,满意度和决策后悔.
主要成果:
- 使用PDA的干预组显示出明显较低的决策冲突得分 (P < 0.001).
- 接受PDA的患者表现出显著更高的知识分数 (P < 0.001).
- 两组之间没有发现患者满意度或决策后悔的显著差异.
结论:
- 一个PDA有效地提高了患者的理解,并减少了个人与PACS或PAC考虑LPI的决策冲突.
- 在眼科治疗决策中,PDA是支持知情选择的宝贵工具.
相关概念视频
Angle Closure Glaucoma: Treatment
1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K
Open Angle Glaucoma: Treatment
961
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
961
Blinding
3.8K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K


